US20070207149A1 - Cancer treatment using viruses and camptothecins - Google Patents
Cancer treatment using viruses and camptothecins Download PDFInfo
- Publication number
- US20070207149A1 US20070207149A1 US11/568,228 US56822805A US2007207149A1 US 20070207149 A1 US20070207149 A1 US 20070207149A1 US 56822805 A US56822805 A US 56822805A US 2007207149 A1 US2007207149 A1 US 2007207149A1
- Authority
- US
- United States
- Prior art keywords
- virus
- subject
- irinotecan
- camptothecin compound
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 37
- 238000011282 treatment Methods 0.000 title abstract description 27
- 201000011510 cancer Diseases 0.000 title description 11
- 241000711404 Avian avulavirus 1 Species 0.000 claims abstract description 51
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims abstract description 47
- 229960004768 irinotecan Drugs 0.000 claims abstract description 46
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229940127093 camptothecin Drugs 0.000 claims abstract description 23
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims abstract description 23
- -1 camptothecin compound Chemical class 0.000 claims abstract description 21
- 229960005395 cetuximab Drugs 0.000 claims abstract description 11
- 102000001301 EGF receptor Human genes 0.000 claims abstract description 8
- 108060006698 EGF receptor Proteins 0.000 claims abstract description 8
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims abstract description 7
- 241000709664 Picornaviridae Species 0.000 claims abstract description 6
- 208000035269 cancer or benign tumor Diseases 0.000 claims abstract description 6
- 229960000303 topotecan Drugs 0.000 claims abstract description 6
- 241000712079 Measles morbillivirus Species 0.000 claims abstract description 4
- 241000700562 Myxoma virus Species 0.000 claims abstract description 4
- 241000710960 Sindbis virus Species 0.000 claims abstract description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 claims abstract description 4
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 22
- 241001466953 Echovirus Species 0.000 claims description 5
- 241000709687 Coxsackievirus Species 0.000 claims description 4
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 claims description 3
- RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 claims description 3
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims description 3
- 229950009213 rubitecan Drugs 0.000 claims description 3
- PAEZRCINULFAGO-OAQYLSRUSA-N (R)-homocamptothecin Chemical compound CC[C@@]1(O)CC(=O)OCC(C2=O)=C1C=C1N2CC2=CC3=CC=CC=C3N=C21 PAEZRCINULFAGO-OAQYLSRUSA-N 0.000 claims description 2
- 241000991587 Enterovirus C Species 0.000 claims description 2
- POADTFBBIXOWFJ-VWLOTQADSA-N cositecan Chemical compound C1=CC=C2C(CC[Si](C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 POADTFBBIXOWFJ-VWLOTQADSA-N 0.000 claims description 2
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 claims description 2
- 229950009429 exatecan Drugs 0.000 claims description 2
- 229950002654 lurtotecan Drugs 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 244000144993 groups of animals Species 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940082789 erbitux Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000309459 oncolytic virus Species 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003236 esophagogastric junction Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000000316 virotherapy Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- camptothecins as anticancer agents is reviewed in Garcia-Carbonero, et al., Clin. Cancer Res. (March 2002) 8: 641-661; and in Pizzolato J F and Saltz L B, The camptothecins. Lancet 2003 361:2235-42. Camptothecins have antitumor activity based on their binding to and inhibition of topoisomerase I, a nuclear enzyme which reduces torsional stress during DNA replication and which has an important role in DNA replication. Topotecan and irinotecan are the two camptothecins have been approved for clinical use by the US Food and Drug Administration (FDA).
- FDA US Food and Drug Administration
- camptothecins are in development as cancer therapeutics (Ulukan and Swaan, (Campothecins: a review of their chemotherapeutic potential. Drugs, 2002, 62:2039-57); and Garcia-Carbonero and Supko, 2002).
- This invention provides a method for treating a mammalian subject having a neoplasm, comprising administering to the subject a virus and a camptothecin compound in a combined amount effective to treat the subject; wherein the virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.
- the treatment further comprises administering to the subject a monoclonal antibody against epidermal growth factor receptor in an amount effective, in combination with the virus and the camptothecin compound, to treat the subject.
- This invention provides for the use of a virus and/or a camptothecin compound in the manufacture of a medicament for treating, in combination with the other ingredient mentioned, a subject having a neoplasm; wherein the virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.
- This invention also provides the use of a monoclonal antibody against epidermal growth factor receptor in the manufacture of a medicament for treating, in combination with a virus as mentioned above and a camptothecin compound, a subject having a neoplasm.
- This invention is based on the finding that anti-cancer viruses and camptothecins in combination are effective against neoplastic cells.
- a mesogenic strain of Newcastle disease virus and irinotecan, a camptothecin compound have demonstrated a greater than additive level of in vivo antitumor activity, as shown in the examples.
- the transitional term “comprising” is open-ended.
- a claim utilizing this term can contain elements in addition to those recited in such claim.
- the claims can read on treatment regimens that also include other therapeutic agents or therapeutic virus doses not specifically recited therein, as long as the recited elements or their equivalent are present.
- NDV Newcastle Disease Virus
- DLT is an abbreviation for dose limiting toxicity.
- plaque-forming unit PFU
- BPFU means billion PFUs.
- PP plaque-purified.
- PPMK107 means plaque-purified Newcastle Disease virus strain MK107.
- PFU/m 2 which is a standard unit for expressing dosages, means PFUs per square meter of patient surface area.
- replication-competent virus refers to a virus that produces infectious progeny in cancer cells.
- the virus is replication-competent.
- the virus when the virus is a Newcastle Disease Virus it can be of low (lentogenic), moderate (mesogenic) or high (velogenic) virulence.
- the level of virulence is determined in accordance with the Mean Death Time in Eggs (MDT) test.
- MDT Mean Death Time in Eggs
- Viruses are classified by the MDT test as lentogenic (MDT>90 hours); mesogenic (MDT from 60-90 hours); and velogenic (MDT ⁇ 60 hours).
- Mesogenic NDV is currently preferred.
- any conventional route or technique for administering viruses to a subject can be utilized.
- routes of administration refer to WO 00/62735.
- the virus is administered systemically, for example intravenously.
- the virus is a mesogenic strain of Newcastle Disease Virus.
- from 12 ⁇ 10 9 to 120 ⁇ 10 9 PFUI/m 2 per dose of a mesogenic strain of Newcastle Disease virus is administered intravenously to a human subject, more preferably from 12 ⁇ 10 9 to 48 ⁇ 10 9 PFU/m 2 per dose.
- mg/m 2 means milligrams per square meter of patient surface area.
- the picornavirus is a poliovirus, an echovirus, or a coxsackievirus.
- coxsackieviruses that are suitable in accordance with this invention include the following types: A21, A13, A15 and A18.
- suitable echoviruses include echovirus type 1.
- camptothecin compound means that class of compounds considered to be camptothecins, camptothecin analogs, camptothecin derivatives or camptothecin conjugates. These compounds are based on the characteristic five-ring backbone of camptothecin:
- camptothecin compounds include irinotecan (CAMPTOSAR; 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin), topotecan (HYCAMPTIN; (S)-9-N;N-dimethylaminoethyl-10-hydroxycamptothecin), 9-aminocamptothecin (9-amino-20(S)-camptothecin), 9-nitrocamptothecin (also called rubitecan), lurtotecan (7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin), exatecan, karenitecin, and a homocamptothecin.
- CAMPTOSAR 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin
- topotecan HYCAMPTIN
- S 9-N
- camptothecin compounds can be found in Garcia-Carbonero, et al., Clin. Cancer Res. (March 2002) 8: 641-661. Examples of camptothecin compounds can also be found in U.S. Pat. No. 4,604,463, No. 6,403,569, and No.
- the camptothecin compound can be administered from one month before administration of the virus until one month after administration of the virus.
- the camptothecin compound and the virus are administered to the subject within a single twenty-four hour period; or the camptothecin compound is administered from twenty-four hours to one month, preferably from twenty-four hours to one week, before administration of the virus; or the camptothecin compound is administered to the subject from twenty-four hours to one month, preferably from twenty-four hours to one week, after administration of the virus.
- the dosing and administration techniques and schedules for camptothecins and anti-cancer viruses are known in the art (See, e.g.
- Irinotecan is usually administered to human patients in a dosage amount of from 62.5 to 125 mg/m 2 four times per week, or more preferably 80 to 125 mg/m 2 four times per week; or from 300 to 350 mg/m 2 once every three weeks, or more preferably 300 to 350 mg/m 2 once every three weeks.
- any antibody against epidermal growth factor receptor can be utilized.
- Chimeric and humanized monoclonal antibodies are preferred.
- suitable anti-EGF antibodies include cetuximab (tradename: ERBITUX), ABX-EGF, MDX-447, h-R3, and EMD-7200 (see Mendelsohn J and Baselga J, “Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer”, 2004 J Clin Oncol 21:2787-2799).
- Cetuximab is preferably administered to human patients intravenously, and is usually administered in an initial intravenous infusion of from 200 to 400 mg/m 2 , followed approximately weekly thereafter by subsequent infusions of from 125 to 250 mg/m 2 .
- the subject that is treated in accordance with this invention can be either a human subject or a non-human mammalian subject.
- any neoplasm can be treated, including but not limited to the following: rectal cancer, pelvic cancer, colon cancer, lung cancer, breast cancer, prostate cancer, glioblastoma, renal cancer, pancreatic cancer, head and neck cancer, endometrial cancer, neuroblastoma, carcinoid, melanoma, ovarian cancer, sarcoma, cancer of the gastro-esophageal junction, gastric cancer, esophageal cancer, liver cancer, and cervical cancer.
- monitoring the treatment is not an essential aspect of the invention, there are techniques for measuring the therapeutic effects of the treatment. These include, measuring the size of the tumor after administration of the virus, and a decrease in tumor size is a positive result.
- the NDV is a triple-plaque purified MK107, which is an attenuated (mesogenic) version of Newcastle Disease Virus, described more fully in International Patent Publication WO 00/62735, published Oct. 26, 2000 (Pro-Virus, Inc.). The entire content of WO 00/62735 is hereby incorporated herein by reference.
- mice were injected subcutaneously with 10 million human HT1080 fibrosarcoma cells. Five days later when the subcutaneous tumors were approximately 100 mm 3 in size, groups of animals were treated intraperitoneally with irinotecan (25 mg/kg) or vehicle. Two days later animals were treated intravenously with either NDV (6 ⁇ 10 6 plaque forming units, PFU) or vehicle. The incidence of complete tumor regression (CR, 100% tumor reduction) was much higher in the group receiving both irinotecan and NDV (60%) than either irinotecan alone (30%) or NDV alone (0%); see Table 1. TABLE 1 Treatment of tumor-bearing mice with irinotecan 2 days before treatment with NDV yields greater complete tumor responses than either agent alone. Treatment Number of Mice CR, % Irinotecan 10 30% NDV 10 0% Both Irinotecan 10 60% and NDV Vehicle Control 10 0%
- mice were injected subcutaneously with 10 million human HT1080 fibrosarcoma cells. Seven days later when the subcutaneous tumors were approximately 125 mm 3 in size, groups of animals were treated intraperitoneally with irinotecan (25 mg/kg) or vehicle and then approximately one hour later they were treated intravenously with either NDV (6 ⁇ 10 6 plaque forming units, PFU) or vehicle.
- NDV plaque forming units
- the incidence of complete tumor regression was much higher in the group receiving both irinotecan and NDV (90%) than either irinotecan alone (50%) or NDV alone (0%), see Table 2.
- Treatment of tumor bearing mice with irinotecan the same day as treatment with NDV yields greater complete tumor responses than either agent alone. Treatment Number of Mice CR, % Irinotecan 10 50% NDV 10 0% Both Irinotecan 10 90% and NDV Vehicle Control 10 0%
- mice were injected subcutaneously with 10 million human HT1080 fibrosarcoma cells. Seven days later when the subcutaneous tumors were approximately 387 mm 3 in size, groups of animals were intravenously with either NDV (6 ⁇ 10 6 plaque forming units, PFU) or vehicle. Two days later, the mice were then treated with treated intraperitoneally with irinotecan (25 mg/kg) or vehicle. The incidence of complete tumor regression (CR, 100% tumor reduction) was much higher in the group receiving both irinotecan and NDV (70%) than either irinotecan alone (10%) or NDV alone (0%), see Table 3. TABLE 3 Treatment of tumor bearing mice with irinotecan two days after treatment with NDV yields greater complete tumor responses than either agent alone. Treatment Number of Mice CR, % Irinotecan 10 10% NDV 10 0% Both Irinotecan 10 70% and NDV Vehicle Control 10 0%
- NDV treatment consist of six total intravenous treatments given at three times per week for two weeks followed by a one week rest period (see Table 4 below).
- the first dose of each cycle consists of 12 to 24 billion PFU/m 2 (administered over 3 hours for course 1 and over 1 hour for all other courses) followed by additional doses of between 24 to 48 billion PFU/m 2 (each dose administered over 1 hour).
- Irinotecan is given for four consecutive weeks on a weekly basis beginning during week 3 or 4 of cycle 1 followed by two weeks without irinotecan therapy (As an example, see Table 4 below).
- NDV treatment consist of six total intravenous treatments given at three times per week for two weeks followed by a one week rest period (see Table 5 below).
- the first dose of six consists of 12 to 24 billion PFU/m 2 (administered over 3 hours for course 1 and over 1 hour for all other courses) followed by a additional doses of 24 to 48 billion PFU/m 2 (each dose administered over 1 hour).
- Patients begin their irinotecan therapy during week 3 and are given one dose every 3 weeks (See Table 5 below). Additional 3 week courses of both NDV and irinotecan are given to the patients. TABLE 5 Combination of treatment of NDV using irinotecan given once every 3 wks.
- Cycles of treatment are repeated every 3 weeks.
- Cancer patients are treated with both NDV and irinotecan as in examples 4 and 5, except that they additionally receive treatment with cetuximab [ERBITUX, a monoclonal antibody (mAb) against the epidermal growth factor receptor (EGFR)].
- cetuximab dosing begins on week 3 or week 4.
- the cetuximab dose is 200 to 400 mg/m 2 for the first intravenous (IV) infusion [administered as a 120 minute IV infusion (with a maximal infusion rate of 5 mL/min)] then 125 to 250 mg/m 2 [infused IV over 60 minutes] administered weekly thereafter.
- IV intravenous
- Some patients may also receive an initial test dose of cetuximab of 20 mg.
- Diphendydramine (50 mg IV) is commonly given to help lessen any infusion reactions due to cetuximab.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- Coadministration of oncolytic viruses with other chemotherapeutic agents is disclosed in WO 00/62735 (pages 35-36). See Kirn D (Cancer Gene Ther 2002; 9:959-960; Virotherapy for cancer: current status, hurdles and future directions) and Bell J C et al. (Cur Gene Ther 2002, 2:243-254; Oncolytic viruses: programmable tumour hunters) for recent reviews on anti-cancer virus therapy. Improvements in efficacy using such virus therapies are important to the field and getting approval and widespread use of the approach. Specifically, a drug which shows supra-additive efficacy with a virus would be most advantageous.
- The use of camptothecins as anticancer agents is reviewed in Garcia-Carbonero, et al., Clin. Cancer Res. (March 2002) 8: 641-661; and in Pizzolato J F and Saltz L B, The camptothecins. Lancet 2003 361:2235-42. Camptothecins have antitumor activity based on their binding to and inhibition of topoisomerase I, a nuclear enzyme which reduces torsional stress during DNA replication and which has an important role in DNA replication. Topotecan and irinotecan are the two camptothecins have been approved for clinical use by the US Food and Drug Administration (FDA). Other camptothecins are in development as cancer therapeutics (Ulukan and Swaan, (Campothecins: a review of their chemotherapeutic potential. Drugs, 2002, 62:2039-57); and Garcia-Carbonero and Supko, 2002).
- The treatment of cancers using certain mutant herpes viruses in combination with any of numerous anticancer agents, including irinotecan and topotecan, is disclosed in U.S. Patent Publication No. 2002/0071832 (Fong, et al.), paragraphs 7 and 40. Methods of treating neoplasias using target cell-specific adenoviral vectors in combination with antineoplastic agents, including irinotecan or topotecan, are disclosed in U.S. Patent Publication No. 2003/0068307 (Yu, et al.) page 13. See also Nemunaitis, et al., Cancer Gene Ther. (2003) 10(5): 341-352; and Meck, et al., Cancer Res. (2001) 61(13): 5083-5089. Combined use of irinotecan and cetuximab was approved in February 2004 by the U.S. FDA to treat colorectal cancer.
- This invention provides a method for treating a mammalian subject having a neoplasm, comprising administering to the subject a virus and a camptothecin compound in a combined amount effective to treat the subject; wherein the virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus. In an embodiment of this invention the treatment further comprises administering to the subject a monoclonal antibody against epidermal growth factor receptor in an amount effective, in combination with the virus and the camptothecin compound, to treat the subject.
- This invention provides for the use of a virus and/or a camptothecin compound in the manufacture of a medicament for treating, in combination with the other ingredient mentioned, a subject having a neoplasm; wherein the virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus. This invention also provides the use of a monoclonal antibody against epidermal growth factor receptor in the manufacture of a medicament for treating, in combination with a virus as mentioned above and a camptothecin compound, a subject having a neoplasm.
- This invention is based on the finding that anti-cancer viruses and camptothecins in combination are effective against neoplastic cells. To illustrate, a mesogenic strain of Newcastle disease virus and irinotecan, a camptothecin compound, have demonstrated a greater than additive level of in vivo antitumor activity, as shown in the examples.
- As used herein the transitional term “comprising” is open-ended. A claim utilizing this term can contain elements in addition to those recited in such claim. Thus, for example, the claims can read on treatment regimens that also include other therapeutic agents or therapeutic virus doses not specifically recited therein, as long as the recited elements or their equivalent are present.
- As used herein “NDV” is an abbreviation for Newcastle Disease Virus. As used herein “DLT” is an abbreviation for dose limiting toxicity. As used herein the term “plaque-forming unit” (PFU) means one infectious virus particle. As used herein “BPFU” means billion PFUs. As used herein “PP” means plaque-purified. Thus, for example PPMK107 means plaque-purified Newcastle Disease virus strain MK107. As used herein “PFU/m2”, which is a standard unit for expressing dosages, means PFUs per square meter of patient surface area. As used herein the term “replication-competent” virus refers to a virus that produces infectious progeny in cancer cells.
- In an embodiment of this invention the virus is replication-competent.
- In accordance with this invention, when the virus is a Newcastle Disease Virus it can be of low (lentogenic), moderate (mesogenic) or high (velogenic) virulence. The level of virulence is determined in accordance with the Mean Death Time in Eggs (MDT) test. (Alexander, “Chapter 27: Newcastle Disease” in Laboratory Manual for the Isolation and Identification of Avian Pathogens, 3rd ed., Purchase, et al. eds. (Kendall/Hunt, Iowa), page 117.) Viruses are classified by the MDT test as lentogenic (MDT>90 hours); mesogenic (MDT from 60-90 hours); and velogenic (MDT<60 hours). Mesogenic NDV is currently preferred.
- In accordance with this invention, any conventional route or technique for administering viruses to a subject can be utilized. For examples of routes of administration refer to WO 00/62735. In one embodiment of this invention, the virus is administered systemically, for example intravenously. For intravenous administration of a therapeutic virus in accordance with this invention, preferably the virus is a mesogenic strain of Newcastle Disease Virus. In a preferred embodiment of this invention, from 12×109 to 120×109 PFUI/m2 per dose of a mesogenic strain of Newcastle Disease virus is administered intravenously to a human subject, more preferably from 12×109 to 48×109 PFU/m2 per dose. As used herein “mg/m2” means milligrams per square meter of patient surface area.
- In embodiments of this invention the picornavirus is a poliovirus, an echovirus, or a coxsackievirus. Examples of coxsackieviruses that are suitable in accordance with this invention include the following types: A21, A13, A15 and A18. Examples of suitable echoviruses include echovirus type 1.
-
- In accordance with this invention any camptothecin compound can be utilized. Examples of camptothecin compounds include irinotecan (CAMPTOSAR; 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin), topotecan (HYCAMPTIN; (S)-9-N;N-dimethylaminoethyl-10-hydroxycamptothecin), 9-aminocamptothecin (9-amino-20(S)-camptothecin), 9-nitrocamptothecin (also called rubitecan), lurtotecan (7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin), exatecan, karenitecin, and a homocamptothecin. The structures and clinical information for some camptothecin compounds can be found in Garcia-Carbonero, et al., Clin. Cancer Res. (March 2002) 8: 641-661. Examples of camptothecin compounds can also be found in U.S. Pat. No. 4,604,463, No. 6,403,569, and No. 5,004,758, and in WO 2004/012661, WO 2003/101998, WO 2003/101996, WO 2003/101406, WO 2003/093274, WO 2003/086471, WO 01/76597, WO 01/64194, WO 00/70275, WO 00/53607, WO 99/17805, WO 99/17804, WO 99/05103, WO 98/35969, WO 97/28164, WO 97/25332, WO 97/16454, the contents of all of which are incorporated herein by reference.
- In accordance with the combination therapy of this invention the camptothecin compound can be administered from one month before administration of the virus until one month after administration of the virus. In more specific embodiments the camptothecin compound and the virus are administered to the subject within a single twenty-four hour period; or the camptothecin compound is administered from twenty-four hours to one month, preferably from twenty-four hours to one week, before administration of the virus; or the camptothecin compound is administered to the subject from twenty-four hours to one month, preferably from twenty-four hours to one week, after administration of the virus. The dosing and administration techniques and schedules for camptothecins and anti-cancer viruses are known in the art (See, e.g. Garcia-Carbonero, et al.; WO 00/62735; WO 2004/000209; and Pecora, et al., J. Clin. Oncol. (2002) 20(9): 2251-2266), and their optimization for a specific patient is within the ability of the skilled clinician. Irinotecan is usually administered to human patients in a dosage amount of from 62.5 to 125 mg/m2 four times per week, or more preferably 80 to 125 mg/m2 four times per week; or from 300 to 350 mg/m2 once every three weeks, or more preferably 300 to 350 mg/m2 once every three weeks.
- In accordance with this invention any antibody against epidermal growth factor receptor can be utilized. Chimeric and humanized monoclonal antibodies are preferred. Examples of suitable anti-EGF antibodies include cetuximab (tradename: ERBITUX), ABX-EGF, MDX-447, h-R3, and EMD-7200 (see Mendelsohn J and Baselga J, “Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer”, 2004 J Clin Oncol 21:2787-2799). Cetuximab is preferably administered to human patients intravenously, and is usually administered in an initial intravenous infusion of from 200 to 400 mg/m2, followed approximately weekly thereafter by subsequent infusions of from 125 to 250 mg/m2.
- The subject that is treated in accordance with this invention can be either a human subject or a non-human mammalian subject. In accordance with this invention, any neoplasm can be treated, including but not limited to the following: rectal cancer, pelvic cancer, colon cancer, lung cancer, breast cancer, prostate cancer, glioblastoma, renal cancer, pancreatic cancer, head and neck cancer, endometrial cancer, neuroblastoma, carcinoid, melanoma, ovarian cancer, sarcoma, cancer of the gastro-esophageal junction, gastric cancer, esophageal cancer, liver cancer, and cervical cancer.
- Although monitoring the treatment is not an essential aspect of the invention, there are techniques for measuring the therapeutic effects of the treatment. These include, measuring the size of the tumor after administration of the virus, and a decrease in tumor size is a positive result.
- The invention will be better understood by reference to the following examples, which illustrate but do not limit the invention described herein. In the following examples 1 to 6, the NDV is a triple-plaque purified MK107, which is an attenuated (mesogenic) version of Newcastle Disease Virus, described more fully in International Patent Publication WO 00/62735, published Oct. 26, 2000 (Pro-Virus, Inc.). The entire content of WO 00/62735 is hereby incorporated herein by reference.
- Athymic mice were injected subcutaneously with 10 million human HT1080 fibrosarcoma cells. Five days later when the subcutaneous tumors were approximately 100 mm3 in size, groups of animals were treated intraperitoneally with irinotecan (25 mg/kg) or vehicle. Two days later animals were treated intravenously with either NDV (6×106 plaque forming units, PFU) or vehicle. The incidence of complete tumor regression (CR, 100% tumor reduction) was much higher in the group receiving both irinotecan and NDV (60%) than either irinotecan alone (30%) or NDV alone (0%); see Table 1.
TABLE 1 Treatment of tumor-bearing mice with irinotecan 2 days before treatment with NDV yields greater complete tumor responses than either agent alone. Treatment Number of Mice CR, % Irinotecan 10 30% NDV 10 0% Both Irinotecan 10 60% and NDV Vehicle Control 10 0% - Athymic mice were injected subcutaneously with 10 million human HT1080 fibrosarcoma cells. Seven days later when the subcutaneous tumors were approximately 125 mm3 in size, groups of animals were treated intraperitoneally with irinotecan (25 mg/kg) or vehicle and then approximately one hour later they were treated intravenously with either NDV (6×106 plaque forming units, PFU) or vehicle. The incidence of complete tumor regression (CR, 100% tumor reduction) was much higher in the group receiving both irinotecan and NDV (90%) than either irinotecan alone (50%) or NDV alone (0%), see Table 2.
TABLE 2 Treatment of tumor bearing mice with irinotecan the same day as treatment with NDV yields greater complete tumor responses than either agent alone. Treatment Number of Mice CR, % Irinotecan 10 50% NDV 10 0% Both Irinotecan 10 90% and NDV Vehicle Control 10 0% - Athymic mice were injected subcutaneously with 10 million human HT1080 fibrosarcoma cells. Seven days later when the subcutaneous tumors were approximately 387 mm3 in size, groups of animals were intravenously with either NDV (6×106 plaque forming units, PFU) or vehicle. Two days later, the mice were then treated with treated intraperitoneally with irinotecan (25 mg/kg) or vehicle. The incidence of complete tumor regression (CR, 100% tumor reduction) was much higher in the group receiving both irinotecan and NDV (70%) than either irinotecan alone (10%) or NDV alone (0%), see Table 3.
TABLE 3 Treatment of tumor bearing mice with irinotecan two days after treatment with NDV yields greater complete tumor responses than either agent alone. Treatment Number of Mice CR, % Irinotecan 10 10% NDV 10 0% Both Irinotecan 10 70% and NDV Vehicle Control 10 0% - Cancer patients are treated with NDV followed by treatment with irinotecan. In each 3 week portion of the 6 week cycle, NDV treatment consist of six total intravenous treatments given at three times per week for two weeks followed by a one week rest period (see Table 4 below). The first dose of each cycle consists of 12 to 24 billion PFU/m2 (administered over 3 hours for course 1 and over 1 hour for all other courses) followed by additional doses of between 24 to 48 billion PFU/m2 (each dose administered over 1 hour). Irinotecan is given for four consecutive weeks on a weekly basis beginning during week 3 or 4 of cycle 1 followed by two weeks without irinotecan therapy (As an example, see Table 4 below). Additional 6 week courses (also termed cycles) of both NDV and irinotecan are given to the patients.
TABLE 4 Combination of treatment of NDV using irinotecan (80 to 125 mg/m2)given weekly ×4. Cycles of treatment are repeated every 6 weeks. Cycle Week NDV? Irinotecan? 1 1 3 doses/wk for two No 2 weeks followed by 1 No 3 week off Yes, one dose over 90 minutes 4 3 doses/wk for two Yes, one dose over 90 minutes 5 weeks followed by 1 Yes, one dose over 90 minutes 6 week off Yes, one dose over 90 minutes 2 1 3 doses/wk for two No 2 weeks followed by 1 No 3 week off Yes, one dose over 90 minutes 4 3 doses/wk for two Yes, one dose over 90 minutes 5 weeks followed by 1 Yes, one dose over 90 minutes 6 week off Yes, one dose over 90 minutes - Cancer patients are treated with NDV followed by treatment with irinotecan. NDV treatment consist of six total intravenous treatments given at three times per week for two weeks followed by a one week rest period (see Table 5 below). The first dose of six consists of 12 to 24 billion PFU/m2 (administered over 3 hours for course 1 and over 1 hour for all other courses) followed by a additional doses of 24 to 48 billion PFU/m2 (each dose administered over 1 hour). Patients begin their irinotecan therapy during week 3 and are given one dose every 3 weeks (See Table 5 below). Additional 3 week courses of both NDV and irinotecan are given to the patients.
TABLE 5 Combination of treatment of NDV using irinotecan given once every 3 wks. Cycles of treatment are repeated every 3 weeks. Cycle Week NDV? Irinotecan? 1 1 3 doses/wk for two No 2 weeks followed by No 3 1 week off Yes, one dose at 300 to 350 mg/m2 over 30 minute intravenous infusion 2 4 3 doses/wk for two No 5 weeks followed by No 6 1 week off Yes, one dose at 300 to 350 mg/m2 over 30 minute intravenous infusion - Cancer patients are treated with both NDV and irinotecan as in examples 4 and 5, except that they additionally receive treatment with cetuximab [ERBITUX, a monoclonal antibody (mAb) against the epidermal growth factor receptor (EGFR)]. Cetuximab dosing begins on week 3 or week 4. The cetuximab dose is 200 to 400 mg/m2 for the first intravenous (IV) infusion [administered as a 120 minute IV infusion (with a maximal infusion rate of 5 mL/min)] then 125 to 250 mg/m2 [infused IV over 60 minutes] administered weekly thereafter. Some patients may also receive an initial test dose of cetuximab of 20 mg. Diphendydramine (50 mg IV) is commonly given to help lessen any infusion reactions due to cetuximab.
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/568,228 US20070207149A1 (en) | 2004-04-27 | 2005-04-26 | Cancer treatment using viruses and camptothecins |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56563104P | 2004-04-27 | 2004-04-27 | |
PCT/US2005/014144 WO2005113018A2 (en) | 2004-04-27 | 2005-04-26 | Cancer treatment using viruses and camptothecins |
US11/568,228 US20070207149A1 (en) | 2004-04-27 | 2005-04-26 | Cancer treatment using viruses and camptothecins |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/014144 A-371-Of-International WO2005113018A2 (en) | 2004-04-27 | 2005-04-26 | Cancer treatment using viruses and camptothecins |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/076,485 Continuation US20140065140A1 (en) | 2004-04-27 | 2013-11-11 | Cancer treatment using viruses and camptothecins |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070207149A1 true US20070207149A1 (en) | 2007-09-06 |
Family
ID=35428865
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/568,228 Abandoned US20070207149A1 (en) | 2004-04-27 | 2005-04-26 | Cancer treatment using viruses and camptothecins |
US14/076,485 Abandoned US20140065140A1 (en) | 2004-04-27 | 2013-11-11 | Cancer treatment using viruses and camptothecins |
US15/195,200 Active US9844574B2 (en) | 2004-04-27 | 2016-06-28 | Cancer treatment using viruses and camptothecins |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/076,485 Abandoned US20140065140A1 (en) | 2004-04-27 | 2013-11-11 | Cancer treatment using viruses and camptothecins |
US15/195,200 Active US9844574B2 (en) | 2004-04-27 | 2016-06-28 | Cancer treatment using viruses and camptothecins |
Country Status (14)
Country | Link |
---|---|
US (3) | US20070207149A1 (en) |
EP (1) | EP1744780B1 (en) |
JP (2) | JP5170741B2 (en) |
KR (1) | KR20070008710A (en) |
CN (1) | CN1946421B (en) |
AU (1) | AU2005244768B2 (en) |
CA (1) | CA2562904C (en) |
HK (1) | HK1096583A1 (en) |
IL (1) | IL178492A (en) |
MX (1) | MXPA06012145A (en) |
NZ (1) | NZ550430A (en) |
RU (2) | RU2408387C2 (en) |
WO (1) | WO2005113018A2 (en) |
ZA (1) | ZA200608119B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193419A1 (en) * | 2005-07-14 | 2008-08-14 | Wellstat Biologics Corporation | Cancer Treatment Using Viruses, Fluoropyrimidines and Camptothecins |
US20110318430A1 (en) * | 2008-12-18 | 2011-12-29 | New York University | Tumor therapy with antitumor agents in combination with sindbis virus-based vectors |
US9844574B2 (en) | 2004-04-27 | 2017-12-19 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ577283A (en) | 2005-03-07 | 2010-11-26 | Robarts Res Inst | Use of a Myxoma virus that does not express functional M135R |
JP2009538935A (en) | 2006-06-01 | 2009-11-12 | ロバーツ リサーチ インスティテュート | Myxoma virus variants for the treatment of cancer |
US20090317456A1 (en) * | 2006-10-13 | 2009-12-24 | Medigene Ag | Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer |
DK2327764T3 (en) | 2009-11-30 | 2012-04-02 | United Cancer Res Inst | New clone of Newcastle disease virus, its preparation and its use in the medical treatment of cancer |
RU2456002C1 (en) * | 2011-03-16 | 2012-07-20 | Алексей Владимирович Дубищев | Diuretic |
WO2015023552A1 (en) * | 2013-08-13 | 2015-02-19 | Bionumerik Pharmaceuticals, Inc. | Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types |
CN107669707A (en) * | 2017-11-16 | 2018-02-09 | 邹罡 | Application of the echovirus as oncolytic virus in antitumor |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4604463A (en) * | 1983-07-14 | 1986-08-05 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
US6403569B1 (en) * | 1999-04-29 | 2002-06-11 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US20020071832A1 (en) * | 2000-06-01 | 2002-06-13 | Yuman Fong | Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
US20020168344A1 (en) * | 2001-02-20 | 2002-11-14 | Oncolytics Biotech, Inc. | Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus |
US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
US20030068307A1 (en) * | 2000-03-24 | 2003-04-10 | De-Chao Yu | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation |
US20040253272A1 (en) * | 2001-08-02 | 2004-12-16 | Yasufumi Kaneda | Process for producing inactivated virus envelopes |
US20050147591A1 (en) * | 1995-10-06 | 2005-07-07 | Hallahan Dennis E. | Methods and compositions for viral enhancement of cell killing |
US7056689B1 (en) * | 1993-04-30 | 2006-06-06 | Wellstat Biologics Corporation | Methods of treating and detecting cancer using viruses |
US20060165656A1 (en) * | 2002-11-01 | 2006-07-27 | Seiji Yamamoto | Medicinal preparation having chemotherapeutic encapsulated therein |
US7223389B2 (en) * | 2001-09-12 | 2007-05-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for treatment of cancer |
US20070128170A1 (en) * | 2001-09-12 | 2007-06-07 | Zichria Zakay-Rones | Compositions of ndv and methods of use thereof for treatment of cancer |
US7279333B2 (en) * | 2000-02-02 | 2007-10-09 | Anges, Mg, Inc. | Virus envelope vector for gene transfer |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
JP3499246B2 (en) | 1995-11-02 | 2004-02-23 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Method for producing camptothecin derivatives |
GB9600438D0 (en) | 1996-01-10 | 1996-03-13 | Pharmacia Spa | Hexacyclic camptothecin analogues, and process for preparing them |
GB9601779D0 (en) | 1996-01-30 | 1996-04-03 | Pharmacia Spa | 9, 10 Disubstituted camptothecin derivatives |
GB9702807D0 (en) | 1997-02-12 | 1997-04-02 | Pharmacia & Upjohn Spa | Alkynyl-substituted camptothecins and process for their preparation |
GB9715821D0 (en) | 1997-07-25 | 1997-10-01 | Pharmacia & Upjohn Spa | Amidino-camptothecin derivatives |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
GB9721070D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Bioactive derivatives of camptothecin |
CZ295775B6 (en) | 1998-08-05 | 2005-11-16 | Aventis Pharma S. A. | Orally administrable agent for restricting or suppressing secondary gastrointestinal effects caused by administration camptothecin derivatives |
DE69901379T2 (en) | 1999-03-09 | 2002-11-07 | Sigma Tau Ind Farmaceuti | Camptothecin derivatives with anti-tumor effects |
AU2905199A (en) * | 1999-03-15 | 2000-10-04 | Trustees Of The University Of Pennsylvania, The | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
CA2370187C (en) * | 1999-04-15 | 2011-08-02 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
EP1261341A2 (en) | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
PL358335A1 (en) | 2000-03-17 | 2004-08-09 | Cell Therapeutics, Inc. | Polyglutamic acid-camptothecin conjugates and methods of preparation |
GB0008928D0 (en) | 2000-04-11 | 2000-05-31 | Pharmacia & Upjohn Spa | A method of administering an antitumour compound |
BR0110877A (en) * | 2000-05-15 | 2003-03-11 | Celgene Corp | Methods of treating primary cancer, increasing the dosage of a topoisomerase inhibitor, reducing or preventing an adverse effect associated with chemotherapy and radiation therapy, increasing the therapeutic efficacy of a topoisomerase inhibitor, and protecting a cancer patient from adverse effects associated with administration of an anti-cancer drug, pharmaceutical composition, dosage form, and kit for use in cancer treatment |
DE10133394A1 (en) * | 2001-07-13 | 2003-01-30 | Merck Patent Gmbh | Liquid formulation containing cetuximab |
CA2454643A1 (en) * | 2001-07-23 | 2003-02-20 | Epidauros Biotechnologie Ag | Methods for the treatment of cancer with irinotecan based on cyp3a5 |
WO2005113013A2 (en) | 2004-05-20 | 2005-12-01 | Theravir Management L.P. | Compositions of ndv and methods of use thereof for treatment of cancer |
TW200306314A (en) | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
US6593334B1 (en) | 2002-05-02 | 2003-07-15 | The University Of North Carolina At Chapel Hill | Camptothecin-taxoid conjugates as antimitotic and antitumor agents |
ITRM20020306A1 (en) | 2002-05-31 | 2003-12-01 | Sigma Tau Ind Farmaceuti | ESTERS IN POSITION 20 OF CAMPTOTECINE. |
AU2003243397A1 (en) | 2002-06-03 | 2003-12-19 | California Pacific Medical Center | Homo-camptothecin derivatives |
AU2003243380A1 (en) | 2002-06-03 | 2003-12-19 | California Pacific Medical Center | Nitrogen-based homo-camptothecin derivatives |
NZ537255A (en) | 2002-06-21 | 2009-04-30 | Wellstat Biologics Corp | Administration of therapeutic viruses |
US6759416B2 (en) | 2002-08-06 | 2004-07-06 | Panorama Research, Inc. | Anticancer conjugates of camptothecin and unsaturated fatty acids |
MXPA06012145A (en) | 2004-04-27 | 2007-01-31 | Wellstat Biologics Corp | Cancer treatment using viruses and camptothecins. |
MXPA06013902A (en) | 2004-05-28 | 2007-01-26 | Pfizer Prod Inc | Method for treating abnormal cell growth. |
CA2612949C (en) | 2005-07-14 | 2015-04-28 | Wellstat Biologics Corporation | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
-
2005
- 2005-04-26 MX MXPA06012145A patent/MXPA06012145A/en active IP Right Grant
- 2005-04-26 CN CN2005800130396A patent/CN1946421B/en not_active Expired - Fee Related
- 2005-04-26 RU RU2006141654/14A patent/RU2408387C2/en not_active IP Right Cessation
- 2005-04-26 CA CA2562904A patent/CA2562904C/en not_active Expired - Fee Related
- 2005-04-26 KR KR1020067024721A patent/KR20070008710A/en not_active Application Discontinuation
- 2005-04-26 NZ NZ550430A patent/NZ550430A/en not_active IP Right Cessation
- 2005-04-26 AU AU2005244768A patent/AU2005244768B2/en not_active Ceased
- 2005-04-26 EP EP05779961.1A patent/EP1744780B1/en not_active Not-in-force
- 2005-04-26 JP JP2007510862A patent/JP5170741B2/en not_active Expired - Fee Related
- 2005-04-26 WO PCT/US2005/014144 patent/WO2005113018A2/en active Application Filing
- 2005-04-26 US US11/568,228 patent/US20070207149A1/en not_active Abandoned
-
2006
- 2006-09-29 ZA ZA2006/08119A patent/ZA200608119B/en unknown
- 2006-10-05 IL IL178492A patent/IL178492A/en not_active IP Right Cessation
-
2007
- 2007-02-02 HK HK07101289.1A patent/HK1096583A1/en not_active IP Right Cessation
-
2010
- 2010-09-21 RU RU2010138887/15A patent/RU2010138887A/en not_active Application Discontinuation
-
2012
- 2012-11-30 JP JP2012262340A patent/JP2013047276A/en not_active Withdrawn
-
2013
- 2013-11-11 US US14/076,485 patent/US20140065140A1/en not_active Abandoned
-
2016
- 2016-06-28 US US15/195,200 patent/US9844574B2/en active Active
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4604463A (en) * | 1983-07-14 | 1986-08-05 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
US7056689B1 (en) * | 1993-04-30 | 2006-06-06 | Wellstat Biologics Corporation | Methods of treating and detecting cancer using viruses |
US20050147591A1 (en) * | 1995-10-06 | 2005-07-07 | Hallahan Dennis E. | Methods and compositions for viral enhancement of cell killing |
US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
US6403569B1 (en) * | 1999-04-29 | 2002-06-11 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US7279333B2 (en) * | 2000-02-02 | 2007-10-09 | Anges, Mg, Inc. | Virus envelope vector for gene transfer |
US20030068307A1 (en) * | 2000-03-24 | 2003-04-10 | De-Chao Yu | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation |
US20020071832A1 (en) * | 2000-06-01 | 2002-06-13 | Yuman Fong | Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
US20020168344A1 (en) * | 2001-02-20 | 2002-11-14 | Oncolytics Biotech, Inc. | Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus |
US20040253272A1 (en) * | 2001-08-02 | 2004-12-16 | Yasufumi Kaneda | Process for producing inactivated virus envelopes |
US7223389B2 (en) * | 2001-09-12 | 2007-05-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for treatment of cancer |
US20070128170A1 (en) * | 2001-09-12 | 2007-06-07 | Zichria Zakay-Rones | Compositions of ndv and methods of use thereof for treatment of cancer |
US20060165656A1 (en) * | 2002-11-01 | 2006-07-27 | Seiji Yamamoto | Medicinal preparation having chemotherapeutic encapsulated therein |
US7427395B2 (en) * | 2002-11-01 | 2008-09-23 | Genomidea Inc. | Chemotherapeutic agent-incorporated pharmaceutical preparation |
Non-Patent Citations (3)
Title |
---|
Cats A. New developments in systemic chemotherapy in advanced colorectal cancer. Scand J Gastroenterol Suppl. 2003;(239):78-86. * |
Ramanathan RK, Belani CP. Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Semin Oncol. 1997 Aug;24(4):440-54. * |
Robert Lorence et al. Poster# 5428, AACR meeting, April 6-10, 2002 in San Francisco. * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9844574B2 (en) | 2004-04-27 | 2017-12-19 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
US20080193419A1 (en) * | 2005-07-14 | 2008-08-14 | Wellstat Biologics Corporation | Cancer Treatment Using Viruses, Fluoropyrimidines and Camptothecins |
US7767200B2 (en) | 2005-07-14 | 2010-08-03 | Wellstat Biologics Corporation | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
US20110117060A1 (en) * | 2005-07-14 | 2011-05-19 | Wellstat Biologics Corporation | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
US20110318430A1 (en) * | 2008-12-18 | 2011-12-29 | New York University | Tumor therapy with antitumor agents in combination with sindbis virus-based vectors |
Also Published As
Publication number | Publication date |
---|---|
JP5170741B2 (en) | 2013-03-27 |
US20140065140A1 (en) | 2014-03-06 |
WO2005113018A3 (en) | 2006-03-02 |
IL178492A (en) | 2010-06-30 |
HK1096583A1 (en) | 2007-06-08 |
CN1946421A (en) | 2007-04-11 |
RU2010138887A (en) | 2012-03-27 |
RU2006141654A (en) | 2008-06-27 |
AU2005244768B2 (en) | 2011-06-09 |
US9844574B2 (en) | 2017-12-19 |
EP1744780A4 (en) | 2009-08-05 |
IL178492A0 (en) | 2007-02-11 |
RU2408387C2 (en) | 2011-01-10 |
CA2562904A1 (en) | 2005-12-01 |
JP2007534761A (en) | 2007-11-29 |
MXPA06012145A (en) | 2007-01-31 |
KR20070008710A (en) | 2007-01-17 |
JP2013047276A (en) | 2013-03-07 |
US20160303175A1 (en) | 2016-10-20 |
CA2562904C (en) | 2013-07-02 |
EP1744780B1 (en) | 2013-08-07 |
NZ550430A (en) | 2009-06-26 |
WO2005113018A2 (en) | 2005-12-01 |
EP1744780A2 (en) | 2007-01-24 |
AU2005244768A1 (en) | 2005-12-01 |
CN1946421B (en) | 2013-07-17 |
ZA200608119B (en) | 2008-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9844574B2 (en) | Cancer treatment using viruses and camptothecins | |
US20110117060A1 (en) | Cancer treatment using viruses, fluoropyrimidines and camptothecins | |
Nemunaitis et al. | Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer | |
AU2003243307B2 (en) | Administration of therapeutic viruses | |
EP2579884B1 (en) | Anti-tumor composition | |
Lange | Evaluation of a novel, suicide gene-armed measles vaccine virus for the treatment of cholangiocarcinoma | |
LÖHR | 19 Experimental treatment of pancreatic cancer M. LÖHR, F. HUMMEL, WH GÜNZBURG and B. SALMONS | |
JP2006524692A (en) | Treatment of hepatocellular carcinoma using therapeutic viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: WELLSTAT BIOLOGICS CORPORATION, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LORENCE, ROBERT M.;ROBERTS, MICHAEL S.;REEL/FRAME:016509/0395 Effective date: 20050422 |
|
AS | Assignment |
Owner name: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE Free format text: SECURITY AGREEMENT;ASSIGNOR:WELLSTAT BIOLOGICS CORPORATION;REEL/FRAME:031029/0801 Effective date: 20130801 |
|
AS | Assignment |
Owner name: PDL BIOPHARMA, INC., NEVADA Free format text: SECURITY AGREEMENT;ASSIGNOR:WELLSTAT BIOLOGICS CORPORATION;REEL/FRAME:031288/0530 Effective date: 20130820 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: WELLSTAT BIOLOGICS CORPORATION, MARYLAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:055060/0338 Effective date: 20210108 |